CClinicalTrials.gg
Status unknownNCT04507165Updated Aug 11, 2020

Opioid-free Anesthesia in VATS Lung Resection

An interventional study of Paravertebral block+Anterior serratus plane block and opioid free anesthesia in Opioid Free Anesthesia, sponsored by Peking University People's Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A comparison of incidences of postoperative opioid-related adverse effects and recovery parameters in patients undergoing video-assisted thoracoscopic surgery (VATS) lung resection receiving opioid or opioid-free general anesthesia (OFA).

Read the detailed description

Video-assisted thoracoscopic surgery (VATS) lung resection is traditionally performed under general anesthesia with opioid-based analgesia. It is associated with higher incidences of respiratory depression, hypotension, postoperative nausea and vomiting (PONV), dizziness, constipation and urinary retention, and more severe acute postoperative pain.

The purpose of our study is to compare the opioid-free general anesthesia with the opioid-based general anesthesia with respect to the primary outcome measures of the total incidence of opioid-related adverse effects (including respiratory depression, hypotension, PONV and dizziness) and secondary outcome measures of incidence of intraoperative and postoperative cardiovascular complications, pain relief, analgesic requirement , and other postoperative recovery parameters [e.g. duration of tracheal extubation, departing from post-anaesthesia care unit (PACU), exhaust, defecation, and stay in hospital postoperatively].

02

Conditions studied

  • Opioid Free Anesthesia

Keywords

  • Opioid Free Anesthesia
  • Video-assisted Thoracoscopic Surgery
03

In context

Lead sponsor

Peking University People's Hospital is the lead sponsor of 584 studies on the registry; 233 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Undergoing VATS lung resection.
  • American Society of Anesthesiologists (ASA) physical status I-II.
  • Agreed to participate in the trial.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • ASA phase III or above.
  • Undergoing emergency surgery.
  • Planning for thoracotomy.
  • Adults protected by law (under judicial protection, guardianship or supervision), people who deprived of their liberty.
  • Patients who have received general anesthesia.
  • Atrioventricular block, sinus node block or intraventricular block.
  • Sinus bradycardia (heart rate is less than 60 beats/min).
  • Preoperative hypotension (systolic blood pressure is less than 90mmHg)
  • Combined with urolithiasis, Meniere syndrome, and vertebral artery stenosis
  • Combined with cerebrovascular disease.
  • Contraindication to NSAIDs drug.
  • Allergic to anesthetics.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    opioid-free general anesthesia

    under opioid-free general anesthesia

    Procedure: Paravertebral block+Anterior serratus plane block · Drug: opioid free anesthesia

  • Active comparator
    opioid based general anesthesia

    under opioid based general anesthesia

    Procedure: Paravertebral block+Anterior serratus plane block · Drug: opioid based anesthesia

Interventions

  • ProcedureParavertebral block+Anterior serratus plane block

    Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by "ice cube" method 15 minutes after the procedure.

    Also known as: nerve block

  • Drugopioid free anesthesia

    Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat. Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively. Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h).

    Also known as: OFA

  • Drugopioid based anesthesia

    Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus). Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively.

    Also known as: Standard anesthesia

06

What researchers measure

Primary outcomes

  1. Total incidence of opioid-related adverse effects of 2 hours, 4 hours, 6 hours, 24 hours and 48 hours postoperation

    The total incidence refers to the sum of the incidence of opioid-related adverse effects at 2h, 4h, 6h, 24h and 48h postoperationOpioid-related adverse effects here including respiratory depression, hypotension, PONV and dizziness.

    Time frame: 2 hours, 4 hours, 6 hours, 24 hours and 48 hours postoperation

Secondary outcomes

  1. Incidence of intraoperative cardiovascular complications

    Including the incidence of arrhythmia, the probability of using hyperensor and hypotensor.

    Time frame: During the operation

  2. Incidence of postoperative cardiovascular complications

    Including the incidence of arrhythmia, the probability of using hypertensor and hypotensor.

    Time frame: Up to 30 days postoperation

  3. Duration of tracheal intubation removing

    From anesthetic discontinuance to tracheal extubation

    Time frame: Up to 2 hours postoperation

  4. Duration of departing from PACU

    From tracheal extubation to Aldrete score\>9. Aldrete score is the standard for departing from PACU which includes five contents to evaluate: activity, breath, blood pressure, state of consciousness and oxygen saturation by pulse oximetry (SpO2). 2 point in total for each content. 2 point refers to the best state, whereas 0 point refers to the worst state. When a patient's total score greater than 9 who will be transferred out of PACU.

    Time frame: Up to 4 hours postoperation

  5. Pain severity

    Using 0-10 numerical rating scale (NRS). The NRS score is ranged from 0 to 10. 0 means without pain. 1-3 means mild pain. 4-6 means moderate pain. 7-9 means severe pain. 10 means intense pain and can't bear.

    Time frame: 2 hours, 4 hours, 6 hours, 24 hours and 48 hours after tracheal extubation

  6. Dosage of opioids

    Total dosage of opioids postoperation

    Time frame: 2 hours, 4 hours, 6 hours, 24 hours and 48 hours after tracheal extubation

  7. Flatus time

    From the operation finished to first-time exhaust

    Time frame: Up to 48 hours postoperation

  8. Defecation time

    From the operation finished to first-time defecation

    Time frame: Up to 48 hours postoperation

  9. Postoperative duration of stay in hospital

    The duration when patients stay in hospital after surgery.

    Time frame: 30 days postoperation

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
08

References and documents

Publications

  • Dinges HC, Otto S, Stay DK, Baumlein S, Waldmann S, Kranke P, Wulf HF, Eberhart LH. Side Effect Rates of Opioids in Equianalgesic Doses via Intravenous Patient-Controlled Analgesia: A Systematic Review and Network Meta-analysis. Anesth Analg. 2019 Oct;129(4):1153-1162. doi: 10.1213/ANE.0000000000003887. PubMed 30418234 ↗
  • Cozowicz C, Poeran J, Zubizarreta N, Liu J, Weinstein SM, Pichler L, Mazumdar M, Memtsoudis SG. Non-opioid analgesic modes of pain management are associated with reduced postoperative complications and resource utilisation: a retrospective study of obstructive sleep apnoea patients undergoing elective joint arthroplasty. Br J Anaesth. 2019 Jan;122(1):131-140. doi: 10.1016/j.bja.2018.08.027. Epub 2018 Oct 27. PubMed 30579391 ↗
  • Forget P. Opioid-free anaesthesia. Why and how? A contextual analysis. Anaesth Crit Care Pain Med. 2019 Apr;38(2):169-172. doi: 10.1016/j.accpm.2018.05.002. Epub 2018 Sep 13. PubMed 29775728 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04507165
Lead sponsor
Peking University People's Hospital
Responsible party
Yi Feng, MD (Chief of the Anesthesiology Department, Peking University People's Hospital) — Principal investigator
First posted
Aug 11, 2020
Start date
Aug 2020 (estimated)
Primary completion
Jul 2021 (estimated)
Completion
Jul 2022 (estimated)
Last update
Aug 11, 2020

Study contacts

Feng Yi, MD,PhD
Contact
yifeng65@sina.com
86-010-88325581
Feng Yi, MD,PhD
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion